Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H11N3O3S |
Molecular Weight | 229.256 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2
InChI
InChIKey=JTEGQNOMFQHVDC-NKWVEPMBSA-N
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175462
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-VATC |
QJ05AR04
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR05
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-VATC |
QJ05AR02
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LAMIVUDINE TEVA PHARMA B.V. (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-VATC |
QJ05AR05
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
KIVEXA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-VATC |
QJ05AR11
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR02
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR11
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/NEV/ZID)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.1
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR16
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
NDF-RT |
N0000175656
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
ZEFFIX (AUTHORIZED: HEPTATIS B, CHRONIC)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR24
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR12
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR07
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
NDF-RT |
N0000009947
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
EPIVIR (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/NEV/STA)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
LIVERTOX |
NBK548553
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR01
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR13
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AR04
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
TRIUMEQ (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-VATC |
QJ05AR01
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LAMIVUDINE/ZIDOVUDINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ATC |
J05AF05
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-VATC |
QJ05AR07
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
COMBIVIR (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
TRIZIVIR (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/ZID)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LAMIVUDINE TEVA (AUTHORIZED: HEPATITIS B, CHRONIC)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
DUTREBIS (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
||
|
WHO-VATC |
QJ05AF05
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000085444
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
6908
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
68244
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | RxNorm | ||
|
63577
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
134678-17-4
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
2T8Q726O95
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
Lamivudine
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
LAMIVUDINE
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | Description: A white or almost white powder.Solubility: Soluble in water; sparingly soluble in methanol R; practically insoluble in acetone R. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Lamivudine should be kept in a well-closed container, protected from light. Additional information: Lamivudine may exhibit polymorphism. Definition: Lamivudine contains not less than 97.0% and not more than 103.0% of C8H11N3O3S, calculated with reference to the dried substance. | ||
|
D019259
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
CHEMBL141
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
C1471
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
7155
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
DD-86
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
DTXSID7023194
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
LAMIVUDINE
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
DB00709
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
760061
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
SUB08392MIG
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
m6672
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | Merck Index | ||
|
2T8Q726O95
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
60825
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
1539
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY | |||
|
1356836
Created by
admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)